A handful of studies have focused on CD44 variant expression in follicular cell-derived thyroid cancers, highlighting its potential as both a diagnostic biomarker and therapeutic target [18,60,61,62,63]. The gene discussed is CD44; the disease is thyroid gland carcinoma.